Rinzimetostat enters Phase 3 mCRPC; thesis turns on whether Phase 1b rPFS signals translate to registrational benefit over AR inhibitor monotherapy

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company developing rinzimetostat, a targeted therapy for metastatic castration-resistant prostate cancer that is not yet approved.

ORIC-944 (rinzimetostat), a PRC2/EZH2 inhibitor, is entering two Phase 3 trials in mCRPC patients on AR inhibitor backbone therapy. The thesis resolves on whether Phase 3 rPFS data confirm the Phase 1b landmark signals that currently support the combination rationale. The primary competitive risk is the established AR inhibitor landscape — enzalutamide, apalutamide, and darolutamide monotherapy set a high efficacy bar, and novel combinations like lutetium-177 PSMA-617 (Pluvicto) expand the standard-of-care competition ORIC must outperform.